Zurich: FDA again rejects Galderma’s Relfydess application
Switzerland-based Galderma Group AG said on July 1, 2026, that the U.S. Food and Drug Administration has again declined to approve its wrinkle-treatment neuromodulator Relfydess (RelabotulinumtoxinA) for sale in the United States. The decision, delivered in a Complete Response Letter following a pre-license inspection of Galderma’s manufacturing facility, cited unresolved...
